Calyxt (CLXT) Stock Price, News & Analysis

Company Overview

Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company to enhance the quality of alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota.

Key Stats

• Today's Range: $6.01 to $7.77
• 50-Day Range: $6.30 to $31.50
• 52-Week Range: $1.25 to $7.77
• Volume: 254,056 shs
• Average Volume: 139,308 shs
• Market Capitalization: $31.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CLXT Stock Analysis - Frequently Asked Questions

How were Calyxt's earnings last quarter?

Calyxt, Inc. (NASDAQ:CLXT) released its earnings results on Monday, May, 1st. The company reported ($5.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.00) by $2.45. The business had revenue of $0.04 million for the quarter. Calyxt had a negative trailing twelve-month return on equity of 259.69% and a negative net margin of 9,979.64%.

When did Calyxt's stock split?

Calyxt's stock reverse split on Thursday, June 1st 2023.The 1-5 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

When did Calyxt IPO?

Calyxt (CLXT) raised $101 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,100,000 shares at a price of $15.00-$18.00 per share. Citigroup, Credit Suisse, JefferiesWells and Fargo Securities served as the underwriters for the IPO and BMO Capital Markets and Ladenburg Thalmann were co-managers.

What other stocks do shareholders of Calyxt own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Calyxt investors own include Cellectis (CLLS), Intel (INTC), Plug Power (PLUG), First Solar (FSLR), Intellia Therapeutics (NTLA), NVIDIA (NVDA) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 5/01/2023
• Today: 8/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CLXT
• CIK: 1705843
• Web: www.calyxt.com
• Phone: (651) 683-2807
• Fax: N/A
• Employees: 48
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): ($3.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.89 million
• Net Margins: -9,979.64%
• Pretax Margin: -9,979.64%
• Return on Equity: -259.69%
• Return on Assets: -83.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.61
• Quick Ratio: 0.61

Sales & Book Value

• Annual Sales: $160 thousand
• Price / Sales: 195.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 11.67

Miscellaneous

• Outstanding Shares: 4,970,000
• Free Float: 4,865,000
• Market Cap: $31.31 million
• Optionable: Not Optionable
• Beta: 1.98